Causaly

Causaly develops an enterprise AI platform for life sciences research and development that retrieves scientific evidence, reasons over it and automates research workflows. The platform combines domain-specialized AI agents operating behind a chat interface with a high-precision Scientific Knowledge Graph containing around 500 million facts and 70 million directional relationships, plus a Commercial Knowledge Graph covering the drug landscape. Core modules include Agentic Research, a Bio Graph for visualizing cause-and-effect biology, pathways and mechanisms, a Pipeline Graph combining pipeline and competitive intelligence with biology, and a Private Data capability that brings customers' internal data and IP into the same workspace.

Use cases span the R&D pipeline from early research through clinical development to post-market, including target identification and prioritization, discovery of novel indications for existing assets, and validation of evidence for regulatory filings (confirming mechanisms of action and producing defensible summaries). Alongside the software, the company offers professional services staffed by PhD scientists and Science and Change Management teams that assist with AI strategy, deployment planning, adoption and codification of customer workflows.

Earlier descriptions of the technology emphasized natural language processing and proprietary machine-reading that interprets biomedical literature by semantics and temporal occurrence to visualize cause-and-effect relationships, with applications across drug discovery, drug safety, clinical trials, epidemiology, health economics, market access, pharmacovigilance and IP functions. In 2026 Causaly also began opening access beyond enterprises through an Early Access program at mycausaly.com aimed at individual researchers, academics, clinicians and small teams, offering Agentic Research, Deep Research, shared Workspaces and reusable research workflows.

Founding story

Causaly was co-founded in 2018 by computer scientists Yiannis Kiachopoulos and Artur Saudabayev, who met at Singularity University's Future Studies program. Both avid readers, they envisioned technology that could read at superhuman speed, extract cause-effect evidence from the literature and communicate findings to the standards of leading scientists, effectively an 'operating system' for biomedical data, at a time when demand for precision medicine was growing while drug discovery lagged. Kiachopoulos, who became CEO, previously consulted at Accenture and holds a bachelor's in Japanese language studies, a master's in computer science and an MBA from Hong Kong University of Science and Technology. Saudabayev, CTO, previously built AI and robotics technologies supporting people with vision and language problems and holds bachelor's and master's degrees from the University of Edinburgh.

Business model

Causaly sells an enterprise AI platform to life sciences organizations, supplemented by professional services in which its PhD scientists and change management teams support deployment, adoption and the codification of customer research workflows. Access is typically initiated through a demo request, and the company has begun opening a separate access track for individuals and small teams via an Early Access waitlist.

Enterprise platform subscriptions to biopharma and life sciences organizations, with accompanying professional services; the company reported tripling revenue in the period before its 2023 Series B.

Traction

At the time of the July 2023 Series B, Causaly had tripled revenue and customers and served 12 of the top 20 pharma companies, with customers including Gilead, the Food and Drug Administration and the National Institute of Environmental Health Sciences, and reported 10x productivity gains for users. Earlier, in 2019, it worked with companies including Novartis as well as hospitals and academia. A published case study reports that ProQR met its 2024 target identification goal by Q3 and achieved 5x productivity compared with using PubMed. In 2026 the company announced partnerships with Microsoft, Sage and Syneos Health.

Latest developments

In September 2025 Causaly introduced an agentic AI platform for life sciences R&D in which specialized agents automate research workflows. During 2026 it announced a collaboration with Microsoft connecting scientific computation to scientific decision-making for target, biomarker, safety and mechanism questions with cited evidence; a partnership with Sage giving its agents access to full-text journal articles; and a partnership with Syneos Health embedding agentic AI into clinical research workflows. It also opened an Early Access program extending the platform to individual researchers, clinicians and small teams.